These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 31030465)
1. Availability of Essential Medicines for Pediatric Oncology in Armenia. Simonyan T; Papyan R; Danielyan S; Sargsyan L; Grigoryan V; Topchyan H; Azaryan A; Tananyan A; Muradyan A; Tamamyan G Asian Pac J Cancer Prev; 2019 Apr; 20(4):991-994. PubMed ID: 31030465 [TBL] [Abstract][Full Text] [Related]
2. Essential medicines for children in Armenia. Kazaryan I; Vardanyan L Int J Risk Saf Med; 2015; 27 Suppl 1():S43-4. PubMed ID: 26639704 [TBL] [Abstract][Full Text] [Related]
3. Chemotherapy and Supportive Care Agents as Essential Medicines for Children With Cancer. Unguru Y; Bernhardt MB; Berg SL; Johnson LM; Pyke-Grimm K; Woodman C; Fernandez CV JAMA Pediatr; 2019 May; 173(5):477-484. PubMed ID: 30830204 [TBL] [Abstract][Full Text] [Related]
5. Are essential medicines in Malaysia accessible, affordable and available? Saleh K; Ibrahim MI Pharm World Sci; 2005 Dec; 27(6):442-6. PubMed ID: 16341951 [TBL] [Abstract][Full Text] [Related]
6. Access to cancer medicines deemed essential by oncologists in 82 countries: an international, cross-sectional survey. Fundytus A; Sengar M; Lombe D; Hopman W; Jalink M; Gyawali B; Trapani D; Roitberg F; De Vries EGE; Moja L; Ilbawi A; Sullivan R; Booth CM Lancet Oncol; 2021 Oct; 22(10):1367-1377. PubMed ID: 34560006 [TBL] [Abstract][Full Text] [Related]
7. Access to Cytotoxic Medicines by Children With Cancer: A Focus on Low and Middle Income Countries. Barr R; Robertson J Pediatr Blood Cancer; 2016 Feb; 63(2):287-91. PubMed ID: 26375626 [TBL] [Abstract][Full Text] [Related]
8. Availability of brands of six essential medicines in 124 pharmacies in Maharashtra. Millard C; Kadam AB; Mahajan R; Pollock AM; Brhlikova P J Glob Health; 2018 Jun; 8(1):010402. PubMed ID: 29423188 [TBL] [Abstract][Full Text] [Related]
9. A survey of availability, price and affordability of essential medicines from 2011 to 2016 in Chinese secondary and tertiary hospitals. Guan X; Hu H; Man C; Shi L Int J Equity Health; 2018 Oct; 17(1):158. PubMed ID: 30340587 [TBL] [Abstract][Full Text] [Related]
10. A multidisciplinary review of the policy, intellectual property rights, and international trade environment for access and affordability to essential cancer medications. Baxi SM; Beall R; Yang J; Mackey TK Global Health; 2019 Sep; 15(1):57. PubMed ID: 31533850 [TBL] [Abstract][Full Text] [Related]
11. Country and regional variations in purchase prices for essential cancer medications. Cuomo RE; Seidman RL; Mackey TK BMC Cancer; 2017 Aug; 17(1):566. PubMed ID: 28836947 [TBL] [Abstract][Full Text] [Related]
12. Availability and affordability of anticancer medicines at the Ocean Road Cancer Institute in Dar es Salaam, Tanzania. Yohana E; Kamuhabwa A; Mujinja P East Afr J Public Health; 2011 Mar; 8(1):52-7. PubMed ID: 22066285 [TBL] [Abstract][Full Text] [Related]
13. Insights from the WHO and National Lists of Essential Medicines: Focus on Pediatric Diabetes Care in Africa. Rowlands A; Ameyaw E; Rutagarama F; Dipesalema J; Majaliwa ES; Mbogo J; Ogle GD; Chanoine JP Horm Res Paediatr; 2018; 90(2):82-92. PubMed ID: 30048982 [TBL] [Abstract][Full Text] [Related]
14. Availability of pediatric-evaluated formulations in Serbia. Božić B; Stupar S; Stupar D; Babić U; Bajčetić M Indian J Pharmacol; 2017; 49(2):189-193. PubMed ID: 28706333 [TBL] [Abstract][Full Text] [Related]
15. Baseline assessment of WHO's target for both availability and affordability of essential medicines to treat non-communicable diseases. Ewen M; Zweekhorst M; Regeer B; Laing R PLoS One; 2017; 12(2):e0171284. PubMed ID: 28170413 [TBL] [Abstract][Full Text] [Related]
16. Access to affordable medicines after health reform: evidence from two cross-sectional surveys in Shaanxi Province, western China. Fang Y; Wagner AK; Yang S; Jiang M; Zhang F; Ross-Degnan D Lancet Glob Health; 2013 Oct; 1(4):e227-37. PubMed ID: 25104348 [TBL] [Abstract][Full Text] [Related]
17. Approaches to improving access to essential cancer medicines in the WHO South-East Asia Region. Chivukula MV; Tisocki K WHO South East Asia J Public Health; 2018 Sep; 7(2):62-66. PubMed ID: 30136662 [TBL] [Abstract][Full Text] [Related]
18. Evaluating drug prices, availability, affordability, and price components: implications for access to drugs in Malaysia. Babar ZU; Ibrahim MI; Singh H; Bukahri NI; Creese A PLoS Med; 2007 Mar; 4(3):e82. PubMed ID: 17388660 [TBL] [Abstract][Full Text] [Related]
19. Universal Access to Essential Medicines: An Evaluation of Nepal's Free Health Care Scheme. Adhikari SR; Pandey AR; Ghimire M; Thapa AK; Lamsal DK J Nepal Health Res Counc; 2018 Mar; 16(1):36-42. PubMed ID: 29717287 [TBL] [Abstract][Full Text] [Related]
20. Availability and affordability of essential medicines for diabetes across high-income, middle-income, and low-income countries: a prospective epidemiological study. Chow CK; Ramasundarahettige C; Hu W; AlHabib KF; Avezum A; Cheng X; Chifamba J; Dagenais G; Dans A; Egbujie BA; Gupta R; Iqbal R; Ismail N; Keskinler MV; Khatib R; Kruger L; Kumar R; Lanas F; Lear S; Lopez-Jaramillo P; McKee M; Mohammadifard N; Mohan V; Mony P; Orlandini A; Rosengren A; Vijayakumar K; Wei L; Yeates K; Yusoff K; Yusuf R; Yusufali A; Zatonska K; Zhou Y; Islam S; Corsi D; Rangarajan S; Teo K; Gerstein HC; Yusuf S; Lancet Diabetes Endocrinol; 2018 Oct; 6(10):798-808. PubMed ID: 30170949 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]